Couverture de Explore Cell Therapy

Explore Cell Therapy

Explore Cell Therapy

De : National Marrow Donor Program/Be The Match
Écouter gratuitement

À propos de ce contenu audio

 In Explore Cell Therapy, we dig into the latest cell and gene therapy research and best practices to help you advance care for patients with hematologic malignancies and disorders. You’ll hear interviews with well-known and up-and-coming physicians in the hematopoietic stem cell transplantation (HCT) and cell and gene therapy field. You’ll receive insights from the National Marrow Donor Program® and our partners into what it takes to connect patients to the best available therapies. In season 2, we examine practice-changing research and hot topics in HCT and other cellular therapies. You’ll hear conversations with experts who specialize in HCT and at hematology/oncology practices.Copyright 2021 All rights reserved. Hygiène et vie saine Maladie et pathologies physiques
Les membres Amazon Prime bénéficient automatiquement de 2 livres audio offerts chez Audible.

Vous êtes membre Amazon Prime ?

Bénéficiez automatiquement de 2 livres audio offerts.
Bonne écoute !
    Épisodes
    • 14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients

      14 - HCT Across MDS Genetic Subtypes, Part I: Expanding Access to Older Patients
      Jan 14 2025

      In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.

      In Part I: Expanding Access to Older Patients, guests explore major advances in transplant for older patients with MDS, highlighting the recent expansion of coverage through the Centers for Medicare and Medicaid Services (CMS), a significant milestone driven by recent studies that demonstrate the safety and efficacy of HCT in patients over 65 years old.

      To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

      Afficher plus Afficher moins
      32 min
    • 14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult

      14 - HCT Across MDS Genetic Subtypes, Part II: The Role of Genetics and Early Consult
      Jan 14 2025

      In this two-part "Explore Cell Therapy" podcast episode, Coleman Lindsley, MD, PhD, and Corey Cutler, MD, MPH, FRCP(C), discuss recent and evolving research supporting the broad benefits of hematopoietic cell transplant (HCT) across all genetic subtypes of myelodysplastic syndrome (MDS), including for patients with high-risk mutations like TP53.

      In Part II, experts stress the importance of early consultation to optimize treatment decisions and ensure equity in access to HCT for older patients in need of a curative treatment option.

      To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

      Afficher plus Afficher moins
      32 min
    • 13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers

      13 - Optimizing Donor Searches in HCT, Part II: Overcoming Barriers
      Nov 20 2024

      This two-part “Explore Cell Therapy” podcast episode dives into recent research on the benefits and challenges of optimizing donor searches for allogeneic hematopoietic cell transplant (HCT). Joseph Pidala, MD, PhD, Moffitt Cancer Center, and Jason Dehn, MPH, NMDPSM, review crucial findings from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1702 trial to shed light on the pivotal role of search prognosis in helping more eligible patients receive HCT.

      In Part II: Overcoming Barriers, the experts review implications for the future of donor search optimization, transplant access and health equity in an increasingly diverse patient population.

      To read bios on the panelists and to access additional resources related to this episode, visit Our Site.

      Afficher plus Afficher moins
      26 min
    Aucun commentaire pour le moment